ABSTRACT

Background. The slopes of estimated glomerular filtration rate (eGFR) equations are used in the longitudinal follow-up of transplant patients. A 30% reduction in eGFR over 2 years is often used to predict the subsequent risk of mortality or end-stage renal disease. Whether, at the individual level, such changes in eGFR correspond to changes in measured GFR (mGFR) is actually unknown.

Methods. The performance of serum creatinine–based eGFR equations was compared with mGFR during the longitudinal follow-up of 20 years in a monocentric study of 417 transplanted patients.

Results. The accuracy within 30% for the eGFR equations varied between 70 and 75%. All eGFR equations showed a similar pattern, very like the mGFR time profiles. Individual changes (slopes) of mGFR or eGFR were predictive of graft loss in the next months or years, following the decline in GFR, with no evidence for a difference. However, although the tendency is the same as for mGFR, the percentage of transplant patients with a >30% GFR decrease in the last period before graft loss is significantly lower for eGFR than for mGFR, with discordant results from mGFR in ~25% of the cases.

Conclusions. All eGFR equations showed similar trends as mGFR, but eGFR predictions may not be very useful at the individual patient level.

Keywords: kidney transplant patients, longitudinal follow-up, measured, and estimated GFR

INTRODUCTION

Measured and estimated glomerular filtration rate (mGFR, eGFR) are particularly important for the longitudinal follow-up of patients after kidney transplantation. There are few literature data on the long-term decline of mGFR in kidney transplant patients because serum creatinine (Scr) or Scr-based eGFR has long been and is still used for the follow-up of transplant...
patients [1, 2]. Commonly used Scr-based eGFR equations [i.e. Modified Diet in Renal Disease (MDRD) [3, 4], Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) [5] and full age spectrum (FAS) [6] equation] have been derived from non-transplant patients and may lack accuracy in the context of kidney transplantation [1, 2, 7–11]. As for longitudinal GFR change, it has been shown that GFR estimating equations are far from perfect to adequately assess the slope of mGFR [12–20]. In transplanted patients, few data are available. Gera et al. [21] described the trend of eGFR to underestimate the true decline of renal graft function. Fauvel et al. [22] showed that all equations failed to detect variations of mGFR <20%. Both studies occurred in a relatively short period after transplantation, as the mean follow-up was 3.4 ± 1.6 years in Gera et al. [21] and within a maximum of 6 years in the Fauvel et al. cohort [22]. Besides GFR slopes, relative variations of GFR are also of interest, as a 30% reduction in eGFR over 2 years has been shown to predict the subsequent risk of mortality or end-stage renal disease [23]. Such an association has also been described in transplanted patients [24]. Whether, at the individual level, such variations of eGFR correspond to variations in mGFR, both for short- and long-term follow-up, is actually unknown.

In this study we sought to evaluate the performance of Scr-based eGFR equations, MDRD, CKD-EPI and FAS compared with mGFR for the longitudinal follow-up in a monochrome study of transplanted patients with mGFR and eGFR every 5 years during a maximal follow-up of 20 years.

**MATERIALS AND METHODS**

**Study population**

We analysed all single kidney transplantations performed in the transplant centre of Saint-Etienne (France) between January 1989 and December 2000 (n = 621). We selected patients with a functioning graft at 5 years post-transplant and for whom inulin mGFR was available at 1 and 5 years post-transplant with concomitant Scr dosage (n = 417). Patients were followed to death or to 31 December 2016. Because few patients’ data were available after 20 years, the follow-up was ended at this time. In total, there were 64 patients with a functioning graft at 20 years post-transplantation and with all data (mGFR, Scr, age and sex) available. The study protocol was approved by the institutional review board and was conducted in accordance with good international clinical practice guidelines.

**Methods**

Transplant patients had a direct measurement of GFR by urinary clearance of inulin, as previously described [25]. Briefly, every 5 years urinary clearance of inulin was conducted according to the continuous infusion method. After a loading dose of 300 mg/kg (half-dose if Scr concentration was >160 μmol/L) of INUTEST 25% (Fresenius, Linz, Austria), a continuous infusion of 400 mg/kg of inulin diluted in a 10% mannitol solution was started. After an equilibration period of 45 min, two or three clearance periods of 30 min each were analysed. Urine samples were collected by spontaneous voiding of the bladder. Blood samples, drawn from the arm opposite to the infusion site, were obtained at the midpoint of each clearance period. Inulin concentrations were quantified according to a standard colorimetric assay (resorcinol method) on a UV1205 spectrophotometer (Shimadzu, Kyoto, Japan) [26]. GFR was measured as the mean of at least two urinary clearances of inulin with the formula UV/P, where U and P are inulin concentrations in urine and plasma, respectively, and V is the urine flow rate (mL/min). GFR was corrected per 1.73 m² of body surface area. In our centre, the mean intra-individual coefficient of variation for this inulin clearance procedure has been previously determined to be 8.4% [25].

Scr was collected on the same day as the inulin clearance measurement and measured using an enzymatic test (Crea Vitros, Ortho-Clinical Diagnostics, Issy-les-Moulineaux, France), equivalent to the isotope dilution mass spectrometry (IDMS) gold standard method. eGFR was calculated using the MDRD [3, 4], CKD-EPI [5] and FAS equations [6]:

- eGFR-MDRD = 175 × Scr⁻¹.159 × Age⁻⁰.²⁰⁷ [× 0.742 if females]
- eGFR-CKD-EPI = 141 × min(SCr/κ)¹ × max(SCr/κ)⁻¹.⁰⁹³ × 0.993²⁸⁰ [× 1.018 if female]
- eGFR-FAS = 107.3/[SCr³] [× 0.988²⁰⁴ eight age >40 years], with Q = 0.70 for females and 0.90 for males.

For the three formulas, Scr is serum creatinine in milligrams per deciliter.

**Statistical analysis**

Descriptive statistics are presented per subgroup using mean ± standard deviation (SD) or median [interquartile range (IQR)] depending on the normality of the data. The performances of the eGFR equations were evaluated in terms of bias, precision and accuracy within 30% (P30). We calculated slopes of mGFR and eGFR in two different ways:

a. Slope = [GFR(j) – GFR(i)]/[Time(j) – Time(i)], where j indicates the time point immediately following the time point i (two consecutive times). This method is very sensitive to accidental errors or variations in the mGFR or eGFR, as it depends only on two points

b. The slope is calculated by using regression analysis using all available data for two, three, four and five consecutive visits. This method takes into account the variability in mGFR and eGFR, as soon as the number of data points is greater than two.

Median slopes between mGFR and eGFR were compared by the Wilcoxon signed-rank test.

Variation of GFR was also studied relative to the preceding GFR value: [GFR(j) – GFR(i)]/GFR. Variation of 10 and 30% were considered, both for eGFR and mGFR at different consecutive time points (5, 10, 15 and 20 years of follow-up). About 10% variation was considered comparable to the intra-individual variation in mGFR measured by inulin clearance and 30% variation was considered because such a variation has been shown to be associated with outcome [24]. Discrepancies between patients reaching 30% variation with mGFR but not eGFR, or vice versa, were presented. Comparison between dependent proportions was performed with McNemar’s exact test. All statistics were determined with SAS version 9.4 (SAS Institute, Cary, NC, USA).

**RESULTS**

Of 621 kidney transplantations performed between 1989 and 2000, 488 recipients had a functioning graft 1 year post-
transplant and had undergone an inulin clearance evaluation. Among them, 417 had a functioning graft 5 years post-transplant along with a usable value of inulin clearance. At 10 years, 312 patients remained, at 15 years, 191 patients still had a functioning graft and at 20 years, there were 64 patients left with a functioning graft. We defined subgroups of patients with the same number of follow-up visits and the same time points, that is, 63 patients had only one follow-up visit (at 1 year after transplantation) and lost their graft before the next planned follow-up visit at which GFR was directly measured (at 5 years). A total of 112 patients had two consecutive follow-up visits (1 and 5 years), 114 patients had three consecutive follow-up visits (1, 5 and 10 years), 120 patients had four consecutive follow-up visits (1, 5, 10 and 15 years) and 59 patients had five consecutive follow-up visits (1, 5, 10, 15 and 20 years). In Table 1 we present the patient characteristics at the time of transplantation of those patients having a functioning graft 1 year post-transplantation. The performance of equations to estimate GFR at different time points (transversal analyses) is summarized in the Supplementary data, Table S1.

Accuracy within 30% for the different equations is between 70 and 75%.

Figure 1 presents the absolute GFR mean values for the recipients with a functioning graft, both for mGFR and eGFR in a longitudinal analysis. This figure shows that both mGFR and eGFR slightly decline over time during the first 15 years post-transplantation, with an acceleration over 15 years post-transplantation. However, this figure should not be overinterpreted, since this acceleration in mGFR and eGFR can be observed in each period immediately preceding graft loss (before the next planned follow-up visit) in every subgroup defined by patients with the same number of consecutive follow-up visits in the period considered (Figure 2). All eGFR equations show a similar pattern, very alike the mGFR time profiles.

In the same view, individual changes (slopes) of mGFR or eGFR were predictive for graft loss in the next months or years, following the decline in GFR. Table 2 illustrates this clearly, showing median slopes between consecutive time points that are becoming steeper with time, showing the largest decline before the period in which the graft is lost. This tendency is not only visible in mGFR, but also in eGFR, as illustrated by FAS in Table 3. In all except for the subgroup with only two points, we could not find evidence for a difference between median slopes in mGFR and FAS. Analogous results are obtained for CKD-EPI and MDRD equations (see Supplementary data, Tables S2a and S2b).

Then we focused on variation of GFR reaching 10 or 30%. Table 4 shows that the percentage of transplant patients with a decrease in mGFR of 10 or 30% between two consecutive time points increases over time, reaching ~50–60% (with a 10% decrease) and 30–40% (with a 30% decrease) in the last period before graft loss. Table 5 shows that eGFR (FAS) decreases >10% in ~50% of the transplant patients in that last period, quite equivalent with mGFR, but only shows 15–25% of transplant patients with >30%. Although the tendency is the same as for mGFR, the percentage of transplant patients with a >30% GFR decrease in the last period before graft loss is (significantly) lower for eGFR than for mGFR. Using the CKD-EPI or MDRD equation instead of the FAS equation leads to the same conclusions regarding variation of GFR of 10 or 30% (see Supplementary data, Tables S3a and S3b) (with concordance rate between eGFR equations >95%).

Table 1. Characteristics at the time of transplantation of patients with a functioning graft at different time points: 1, 5, 10, 15 and 20 years post-transplantation

| N   | Time (year) | Age (years) | Male (%) | Pre-emptive (%) | Retransplant (%) | Cause of renal disease (%)^a |
|-----|-------------|-------------|----------|-----------------|-----------------|--------------------------------|
| 488 | 1           | 45.4 ± 12.9 | 69.5     | 8.9             | 15.8            | 1.0 32.4 7.8 13.9 7.6 12.1 25.2 |
| 417 | 5           | 45.2 ± 12.5 | 69.5     | 8.9             | 15.6            | 1.0 33.5 7.2 14.1 7.2 12.5 24.5 |
| 312 | 10          | 45.0 ± 12.2 | 71.5     | 8.4             | 15.1            | 1.0 32.0 6.4 15.1 6.4 11.9 27.2 |
| 191 | 15          | 43.0 ± 12.2 | 77.0     | 10.0            | 13.0            | 1.0 30.4 5.8 13.1 7.3 12.0 30.4 |
| 64  | 20          | 40.7 ± 11.3 | 71.9     | 17.2            | 9.4             | 1.6 26.6 1.6 7.8 6.2 10.9 45.3 |

^a1, diabetes; 2, glomerulopathy; 3, hypertension; 4, polycystic kidney disease; 5, interstitial nephritis; 6, other; 7, unknown. ^bAge at transplantation.
Table 6 shows whether variations in eGFR (using different equations) and mGFR are concordant or not. In other words, when a change of 30% in mGFR is reached in a given patient, is a change in eGFR of 30% also obtained? The ability of the FAS or CKD-EPI equation to classify patients with variations of $\Delta$GFR $< -30\%$ (or $-10\%$) is the same (concordance of 90–95% between the two equations), whereas the discordance of classification of both equations with mGFR is 30–40% (for the criterion $\Delta$GFR $< -10\%$) and 20–30% (for the criterion $\Delta$GFR $< -30\%$). The same conclusions are drawn with the MDRD equation (data not shown).

**DISCUSSION**

In this study we have shown that the current equations used to estimate GFR correctly reflect the trajectory of mGFR in a longitudinal analysis of GFR results in renal transplant patients followed over a long period of time (up to 20 years of follow-up). The ability of eGFR to reflect the trajectory of mGFR is actually good at the population level, and comparing equations between them, we cannot prove the superiority of one equation compared with the others. As a specific example, eGFR decline, as well as mGFR, accelerates in the 5-year period preceding the loss of the graft, as expected [27]. Although there were small differences between slopes based on mGFR and eGFR.
Table 3. Median slope (quartile 1–quartile 3) for FAS calculated from two consecutive time points and from linear regression using all available time points

| Group              | 1–5 years | 5–10 years | 10–15 years | 15–20 years | First–last time point | From regression |
|--------------------|-----------|------------|-------------|-------------|-----------------------|-----------------|
| Two visits (n = 112) | –0.91     | –          | –           | –           | –0.91                | –0.91           |
|                    | (–3.35–0.78)* |           |             |             | (–3.35–0.78)         | (–3.35–0.78)*   |
| Three visits (n = 114) | –0.09     | –0.92      | –           | –           | (–2.01 to 0.11)      | (–2.25 to 0.01) |
|                    | (–1.87 to 0.08) | –1.24      |             |             | (–1.20 to 0.17)      | (–1.12 to 0.20) |
| Four visits (n = 120) | 0.46      | –0.27      | –           | –1.28       | –0.41                | –0.44           |
|                    | (–2.16 to 1.89) | (–1.22 to 1.31) | (–1.49 to 1.07) | (–2.87 to 0.28) | (–0.87 to 0.08) | (–0.89 to 0.20) |
| Five visits (n = 59)  | –0.34     | 0.10       | –0.29       | –1.28       | –0.37                | –0.23           |
|                    | (–2.16 to 1.89) | (–1.22 to 1.31) | (–1.49 to 1.07) | (–2.87 to 0.28) | (–0.87 to 0.08) | (–0.89 to 0.20) |

*Indicates a significant difference (P < 0.05) from the equivalent parameter in Table 2.

Table 4. Percentage of patients (95% CI) with a decrease in mGFR of >10% and >30% calculated from two consecutive measurements and from the first (baseline value at 1 year) and the last available time points

| Group              | 1–5 years | 5–10 years | 10–15 years | 15–20 years | First–last time point |
|--------------------|-----------|------------|-------------|-------------|-----------------------|
| mGFR >10%          |           |            |             |             |                       |
| Two visits (n = 112) | 38.4      | –          | –           | –           | 38.4                  |
|                    | (29.2–47.5) |           |             |             | (29.2–47.5)           |
| Three visits (n = 114) | 34.2      | 61.4       | –           | –           | 62.3                  |
|                    | (25.4–43.1) | (52.3–70.5) |             |             | (53.2–71.3)           |
| Four visits (n = 120) | 25.8      | 35.8       | 50.0        | –           | 46.7                  |
|                    | (17.9–33.8) | (27.1–44.5) | (40.9–59.1) |             | (37.6–55.7)           |
| Five visits (n = 59)  | 35.6      | 44.1       | 37.3        | 62.7        | 54.2                  |
|                    | (23.0–48.2) | (31.0–57.1) | (24.6–50.0) | (50.0–75.4) | (41.1–67.3)           |
| mGFR >30%          |           |            |             |             |                       |
| Two visits (n = 112) | 26.8      | –          | –           | –           | 26.8                  |
|                    | (18.5–35.1) |           |             |             | (18.5–35.1)           |
| Three visits (n = 114) | 19.3      | 39.5       | –           | –           | 38.6                  |
|                    | (11.9–26.7) | (30.4–48.6) |             |             | (29.5–47.7)           |
| Four visits (n = 120) | 9.2       | 16.7       | 30.0        | –           | 30.8                  |
|                    | (3.9–14.4) | (9.9–23.4) | (21.7–38.3) |             | (22.5–39.2)           |
| Five visits (n = 59)  | 10.2      | 11.9       | 13.6        | 33.9        | 35.6                  |
|                    | (2.2–18.1) | (6.0–20.4) | (4.6–22.6) | (21.5–46.3) | (23.0–48.2)           |

Table 5. Percentage of patients (95% CI) with a decrease in FAS >10% and >30% calculated from consecutive measurements and from the first (baseline value at 1 year) and last available time points

| Group              | 1–5 years | 5–10 years | 10–15 years | 15–20 years | First–last time point |
|--------------------|-----------|------------|-------------|-------------|-----------------------|
| FAS >10%           |           |            |             |             |                       |
| Two visits (n = 112) | 50.0      | –          | –           | –           | 50.0                  |
|                    | (40.6–59.4)* |           |             |             | (40.6–59.4)           |
| Three visits (n = 114) | 28.9      | 51.8       | –           | –           | 62.3                  |
|                    | (20.5–37.4) | (42.4–61.1) |             |             | (53.2–71.3)           |
| Four visits (n = 120) | 24.2      | 36.7       | 54.2        | –           | 52.5                  |
|                    | (16.4–31.9) | (27.9–45.4) | (45.1–63.2) |             | (43.4–61.6)           |
| Five visits (n = 59)  | 33.9      | 25.4       | 30.5        | 52.5        | 50.8                  |
|                    | (21.5–46.3) | (14.0–36.9)* | (18.4–42.6) | (39.4–65.7) | (37.7–64.0)           |
| FAS >30%           |           |            |             |             |                       |
| Two visits (n = 112) | 24.1      | –          | –           | –           | 24.1                  |
|                    | (16.1–32.2) |           |             |             | (16.1–32.2)           |
| Three visits (n = 114) | 13.2      | 26.3       | –           | –           | 34.2                  |
|                    | (6.9–19.5) | (18.1–34.5)* |             |             | (25.3–43.1)           |
| Four visits (n = 120) | 6.7       | 9.2        | 17.5        | –           | 26.7                  |
|                    | (2.1–11.2) | (3.9–14.4) | (10.6–24.4)* |             | (18.6–34.7)           |
| Five visits (n = 59)  | 5.1       | 1.7        | 1.7         | 20.3        | 27.1                  |
|                    | (0.0–10.9) | (0.0–5.1) | (0.0–5.1)* | (9.8–30.9) | (15.4–38.8)           |

*Indicates a significant difference (P < 0.05) with the corresponding result in Table 4.
In conclusion, we showed that estimating equations correctly predict the slope or trajectory of mGFR in renal transplant patients in the long term and at the population level. However, at the individual level and to detect variations of mGFR potentially impacting clinical decisions, all current estimating equations lack precision and discordant results with large (−30%) differences from mGFR have been observed in 25% of the cases. We therefore believe that our results encourage the follow-up of transplant patients not solely based on eGFR, but on mGFR at specific follow-up moments post-transplantation [9, 38–40].

SUPPLEMENTARY DATA
Supplementary data are available at CKJ online.

AUTHORS’ CONTRIBUTIONS
H.P. participated in data analysis and writing of this article. A.D. and N.M. participated in the performance of the research. C.M. participated in research design, the performance of the research and the writing of the article. P.D. participated in data analysis and writing of the article.

CONFICT OF INTEREST STATEMENT
None declared.
REFERENCES

1. Masson I, Flamant M, Maillard N et al. MDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients. Transplantation 2013; 95: 1211–1217
2. White CA, Huang D, Akbani A et al. Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review. Am J Kidney Dis 2008; 51: 1005–1015
3. Levey AS, Bosch JP, Lewis JB et al. Estimated glomerular filtration rate in renal transplantation: the nephrologist in the mist. Transplantation 2015; 99: 2625–2633
4. Boren F, Hadj-Aissa A, Dubourg L et al. Estimating glomerular filtration rate in kidney transplant recipients: performance over time of four creatinine-based formulas. Transplantation 2011; 92: 1005–1011
5. Padala S, Tighiouart H, Inker LA et al. Accuracy of a GFR estimating equation over time in people with a wide range of kidney function. Am J Kidney Dis 2012; 60: 217–224
6. van Rijn MHC, Metzger M, Flamant M et al. Performance of creatinine-based equations for estimating glomerular filtration rate changes over time. Nephrol Dial Transplant 2018; doi: 10.1093/ndt/gfy278
7. de Boer IH, Sun W, Cleary PA et al. Longitudinal changes in estimated and measured GFR in type 1 diabetes. J Am Soc Nephrol 2014; 25: 810–818
8. Lee D, Levin A, Roger SD et al. Longitudinal analysis of performance of estimated glomerular filtration rate as renal function declines in chronic kidney disease. Nephrol Dial Transplant 2008; 24: 109–116
9. Wood AJ, Churilov L, Perera N et al. Estimating glomerular filtration rate: performance of the CKD-EPI equation over time in patients with type 2 diabetes. J Diabetes Complications 2016; 30: 49–54
10. Gaspari F, Ruggenenti P, Porrini E et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013; 84: 164–173
11. Xie D, Joffe MM, Brunelli SM et al. A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1332–1338
12. Tent H, Waanders F, Krikken JA et al. Performance of MDRD study and CKD-EPI equations for long-term follow-up of nondiabetic patients with chronic kidney disease. Nephrol Dial Transplant 2012; 27(Suppl 3): ii89–iii95
13. Rule AD, Torres VE, Chapman AB et al. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol 2006; 17: 854–862
14. Gera M, Slezk JM, Rule AD et al. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. Am J Transplant 2007; 7: 880–887
15. Fauvel JP, Hadj-Aissa A, Buron F et al. Performance of estimated glomerular filtration rates to monitor change in renal function in kidney transplant recipients. Nephrol Dial Transplant 2013; 28: 3096–3100
16. Coresh J, Turin TC, Matsushita K et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311: 2518–2531
17. Clayton PA, Lim WH, Wong G et al. Relationship between eGFR decline and hard outcomes after kidney transplants. J Am Soc Nephrol 2016; 27: 3440–3446
18. Mariat C, Alamartine E, Barthelemy JC et al. Assessing renal graft function in clinical trials: can tests predicting glomerular filtration rate substitute for a reference method? Kidney Int 2004; 65: 289–297
19. Delanaye P, Buren F, Souvignet M et al. Comparison of acid and enzymatic methods for insulin dosage: analytical performances and impact on glomerular filtration rate evaluation. Clin Chim Acta 2012; 413: 556–560
20. Moranne O, Maillard N, Fafn C et al. Rate of renal graft function decline after one year is a strong predictor of all-cause mortality. J Am Soc Nephrol 2013; 13: 695–706
21. Murata B, Baumann NA, Saenger AK et al. Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. Clin J Am Soc Nephrol 2011; 6: 1963–1972
22. Poge U, Gerhardt T, Stoffel-Wagner B et al. Validation of the CKD-EPI formula in patients after renal transplantation. Nephrol Dial Transplant 2011; 26: 4104–4108
23. Kukla A, El-Shahawi Y, Leister E et al. GFR-estimating models for the estimation of glomerular filtration rate decline in stages 1 and 2 chronic kidney disease using CKD-EPI equation. J Nephrol Dial 2007; 84: 490–497
24. Kuster N, Cristol JP, Cavalier E et al. Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation. J Am Soc Nephrol 2014; 27: 467–475
25. Lee EF, Jeon J, Lee KW et al. The combination of area under the curve and percentage change in estimated glomerular filtration rate predicts long-term outcome of kidney transplants. Am J Transplant 2019; doi: 10.1111/ajt.15711
36. Masson I, Maillard N, Tack I et al. GFR estimation using standardized cystatin C in kidney transplant recipients. Am J Kidney Dis 2013; 61: 279–284
37. Delanaye P, Krzesinski JM. Indexing of renal function parameters by body surface area: intelligence or folly? Nephron Clin Pract 2011; 119: c289–c292
38. Porrini E, Ruggenenti P, Luis-Lima S et al. Estimated GFR: time for a critical appraisal. Nat Rev Nephrol 2019; 15: 177–190
39. Agarwal R, Delanaye P. Glomerular filtration rate: when to measure and in which patients? Nephrol Dial Transplant 2019; 34: 2001–2007.
40. Delanaye P, Melsom T, Ebert N et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: why to measure glomerular filtration rate with iohexol? Clin Kidney J 2016; 9: 700–704